NANOLOGY


Associated tags: Toxicity, Neoplasm, Taxane, Research, Biotechnology, Pharmaceutical, Clinical Trials, Oncology, Health, FDA, Pharmaceutical industry, Medical imaging, LSAM, Patient, Safety, Pancreas, Lung, U.S. FDA, Science, MD, Clinical trial

Locations: TEXAS, UNITED STATES, NORTH AMERICA, CHICAGO, EUROPE, CHINA, AUSTRALIA, INDONESIA, RUSSIA, JAPAN, US, CANADA

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

Retrieved on: 
Tuesday, December 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Spleen, Immunotherapy, Conference, TME, LSAM, American Conference, Flow cytometry, Blood, Mouse, Paclitaxel, Immunomodulation, Society, Poster, Safety, Lung cancer, NK, NMIBC, SITC, Vaccine

NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.
  • The poster was authored by clinical investigators Hiren Mehta , Abhishek Biswas , Sarah Wang , Jason Akulian , Christine Argento , et.al.
  • Summarizing presented data:
    The early phase lung cancer trial demonstrated safety and tolerability of intratumoral (IT) LSAM-PTX in combination with various concurrent therapies, including systemic immunotherapy.
  • Summarizing presented data:
    Immunophenotyping in 3 diverse tumor settings found commonalities in antitumor immunomodulation following local LSAM-DTX, including changes in T cells and MDSCs.

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, October 10, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Immunosuppression, TME, Pancreatitis, SOC, Cedars-Sinai Medical Center, AACR, Standard of care, LAPC, University, Survival, Disease, Abdominal pain, Nausea, University of Illinois College of Medicine, Immunotherapy, Pancreatic cancer, LSAM, Immunomodulation, Paclitaxel, Plasma, Parkview Health, Illinois College, Tumor necrosis factor, Tissue, NK, Phenotype, Blood, Conference, Research, Pharmaceutical industry, Dietary supplement, Vaccine, Medical device, Medical imaging, Pancreas, MD, Safety

The research article entitled Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome provides safety and response data from dose escalation and 2-injection cohorts.

Key Points: 
  • The research article entitled Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome provides safety and response data from dose escalation and 2-injection cohorts.
  • “Pancreatic cancer is among the most lethal cancers with 5-year survival of only 12%,” said lead investigator and author, Neil Sharma, MD.
  • The research article reports data from evaluable subjects in the first two cohorts while the third is pending final readout.
  • Additionally, two posters presented downstaging and immune data from the Phase 2 trial following IT LSAM-PTX at the recent AACR Special Conference on Pancreatic Cancer.

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Docetaxel, Ohio State University, Radiation, LSAM, Intraductal papillary mucinous neoplasm, Ohio State University Wexner Medical Center, Cyst, Clinical trial, Research, SOC, Doctor of Philosophy, ASCO, DDW, Patient, Risk, Ablation, Toxic epidermal necrolysis, Pancreatic cyst, Safety, Pharmaceutical industry, MD

NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.
  • The DDW poster entitled “Intracystic Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX) for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol,” was presented by the research team of Somashekar Krishna, MD of The Ohio State University Wexner Medical Center.
  • The expanded access protocol prospectively evaluated safety and response of six subjects from the trial who received additional doses of LSAM-PTX.
  • “In this protocol, intracystic LSAM-PTX was safe and resulted in cyst volume and surface area reduction, morphological changes, and loss of pathogenic mutations,” said Dr. Krishna.

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Retrieved on: 
Tuesday, March 7, 2023
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, MD, Pancreas, Treatment, Toxic epidermal necrolysis, Toxicity, Patent, Prostate, ICIS, LSAM, Lung, Patient, Neoplasm, Immune system, Primary tumor, Pharmaceutical industry, Medical imaging, Cancer

The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.

Key Points: 
  • The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.
  • ICIs are often used in combination with other systemic cancer therapies particularly in the treatment of solid tumors to prime the immune system to increase response.
  • “The Cancer Research Institute estimates more than 5000 clinical trials are underway worldwide with immune checkpoint inhibitors; many are combination trials with other systemic cancer agents in solid tumors.” said Gere DiZerega, MD, NanOlogy Chief Medical Officer.
  • “The goal is to identify which combinations can increase the immune response thereby increasing the overall solid tumor response to treatment.

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

Retrieved on: 
Tuesday, December 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Patient, Cyst, U.S. FDA, Neoplasm, Treatment, Paclitaxel, Patent, Pancreatic cancer, Toxic leukoencephalopathy, LSAM, FDA, Safety, Plasma, LAPC, Pancreas, Pancreatic cyst, Prostate, Lung, Research, Week, Medical imaging, Pharmaceutical industry

Certain mucinous pancreatic cysts are at high risk for progression to pancreatic cancer.

Key Points: 
  • Certain mucinous pancreatic cysts are at high risk for progression to pancreatic cancer.
  • Results from the trial are intended to support future research in this patient subset to evaluate whether intracystic LSAM-PTX can decrease the rate of progression.
  • The treatment is covered by a recently issued US patent ( 11,523,983 ) entitled Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles.
  • Enrollment is also complete (n=54) in a NanOlogy-sponsored clinical trial of intratumoral (IT) LSAM-PTX with systemic chemotherapy in locally advanced pancreatic cancer (LAPC).

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Retrieved on: 
Friday, November 11, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, U.S. FDA, Lung, SOC, Radiation, FDA, Survival, Pancreas, Plasma, Private Securities Litigation Reform Act, Mortality, Trial of the century, Cancer, III, Lung cancer, Toxicity, Technology, View, Patient, ICI, Safety, Paclitaxel, Neoplasm, Taxane, Method, ICIS, Standard of care, Prostate, LSAM, Medical imaging, Pharmaceutical industry, LLC

NanOlogy LLC , a clinical-stage interventional oncology drug company, announced enrollment is complete in a Phase 2a trial of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) with standard of care (SOC) therapy in patients with nonoperable lung cancer.

Key Points: 
  • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced enrollment is complete in a Phase 2a trial of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) with standard of care (SOC) therapy in patients with nonoperable lung cancer.
  • The primary outcome measure for the trial is safety, as determined by treatment emergent adverse events.
  • Lung cancer has the highest mortality of any cancer with 2.2 million new cases and 1.8 million deaths estimated globally in 2020 by GLOBOCAN .
  • ICIs are rapidly becoming a SOC for the treatment of lung cancer often combined with other agents to increase response.

NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX

Retrieved on: 
Monday, October 3, 2022
Oncology, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Squamous cell carcinoma, Journal, Kidney, U.S. FDA, Immunomodulation, FDA, Taxane, Prostate, Bladder cancer, Review, Private Securities Litigation Reform Act, Neoplasm, Pancreas, Clinical trial, The Journal of Urology, Translational research, Technology, Method, Lung, LSAM, View, Toxicity, Pharmaceutical industry, Medical imaging, Vaccine, Urology, LLC, Oncology, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology

NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel (LSAM-DTX), has been published in Drug Delivery and Translational Research (DDTR) .

Key Points: 
  • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel (LSAM-DTX), has been published in Drug Delivery and Translational Research (DDTR) .
  • The articles also follows an earlier review of preclinical and clinical research supporting another NanOlogy investigational drug, large surface area microparticle paclitaxel (LSAM-PTX), published in DDTR in 2020.
  • LSAMDTX in combination with an immune checkpoint inhibitor demonstrated synergy in a preclinical metastatic breast cancer model.
  • In addition to LSAM-DTX, NanOlogy clinical programs have advanced tumor-directed LSAM-PTX in pancreas, lung, peritoneal, ovarian, prostate, and dermal cancers.

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Monday, August 1, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Diagnosis, U.S. FDA, Â, Ovary, Taxane, Bladder cancer, Safety, Tumor microenvironment, Cystoscopy, Lung, Clinical trial, Method, Urology, SEER, BCG, HIV disease progression rates, University of Texas Health Science Center at San Antonio, Johns Hopkins University, Journal, Technology, Prostate, Cystectomy, Biopsy, Docetaxel, Johns Hopkins School of Medicine, Quality of life, Recurrence, FDA, Blood, Neoplasm, Treatment, View, Worldwide, Toxicity, NMIBC, Maintenance, The New England Journal of Medicine, TURBT, Bacillus, Associate, Private Securities Litigation Reform Act, Pancreas, Risk, UT Health East Texas - North Campus, Patient, NK, Medical imaging, Pharmaceutical industry, Dietary supplement, LLC, MD

NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology .

Key Points: 
  • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology .
  • The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer presents safety and response data from the multi-site study ( NCT03636256 ).
  • Worldwide, an estimated 573,000 people were diagnosed with bladder cancer in 2020 and 81,000 people will be diagnosed with bladder cancer in the United States in 2022.
  • In this Phase 1/2 clinical trial, LSAM-DTX showed promising signs of preventing disease progression and interesting immunogenic effects with minimal adverse events.

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

Retrieved on: 
Tuesday, May 3, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Treatment, Ovary, Private Securities Litigation Reform Act, Pain, Breast cancer, Memorial Sloan Kettering Cancer Center, Taxane, Safety, RECIST, Research, Bleeding, Â, Patient, Infection, Partnership, Clinical trial, Lung, FDA, USC Norris Comprehensive Cancer Center, Paclitaxel, Skin, Cleveland Clinic, Quality of life, Method, BCRF, View, Pancreas, Management of prostate cancer, Breast Cancer Research and Treatment, Technology, U.S. FDA, Medical imaging, Pharmaceutical industry, LLC, MD

NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of topical submicron particle paclitaxel (SOR007) in cutaneous metastases of breast cancer (CMBOC) have been published in Breast Cancer Research and Treatment .

Key Points: 
  • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of topical submicron particle paclitaxel (SOR007) in cutaneous metastases of breast cancer (CMBOC) have been published in Breast Cancer Research and Treatment .
  • The research article entitled Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer presents final safety and response data from the multi-site study ( NCT03101358 ).
  • SOR007 was well tolerated at all concentrations allowing the 2.0% concentration to continue to the dose expansion phase of the trial.
  • In addition to SOR0007, NanOlogy clinical programs have advanced tumor-directed investigational drugs in pancreas, lung, bladder, peritoneal, ovarian, and prostate cancers.

Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care

Retrieved on: 
Tuesday, November 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Mortality, Safety, Indiana University School of Medicine, View, ACG, Private Securities Litigation Reform Act, Texas Tech University Health Sciences Center, Neoplasm, Clinical trial, Baylor College of Medicine, Method, U.S. FDA, Technology, SOC, Research, Paclitaxel, Cancer, American College, Pancreatic cancer, American College of Gastroenterology, American Cancer Society, Baylor University, Toxicity, Assistant professor, Lung, LSAM, Patient, Abdominal pain, FDA, API, Death, Pharmaceutical industry, Medical device, Medical imaging

NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today a single-site analysis of data from an ongoing Phase 2a clinical trial ( NCT03077685 ) of intratumoral (IT) NanoPac (large surface area microparticle [LSAM] paclitaxel) suspension showed improved resection rates in locally advanced pancreatic cancer (LAPC).

Key Points: 
  • NanOlogy LLC , a clinical-stage interventional oncology drug company, announced today a single-site analysis of data from an ongoing Phase 2a clinical trial ( NCT03077685 ) of intratumoral (IT) NanoPac (large surface area microparticle [LSAM] paclitaxel) suspension showed improved resection rates in locally advanced pancreatic cancer (LAPC).
  • The presentation entitled Improved Resection Rates in Locally Advanced Pancreatic Cancer Following EUS-FNI of Large Surface Area Microparticle Paclitaxel described results from a single clinical site analysis of a subset of nonsurgical patients (n=13) treated with two monthly administrations of IT NanoPac via endoscopic ultrasound guided fine needle injection (EUS-FNI) together with neoadjuvant standard of care.
  • 7/13 (54%) of subjects considered nonsurgical at enrollment were restaged to surgical after addition of IT NanoPac to neoadjuvant standard of care (SOC) therapy.
  • The American Cancer Society estimates nearly 58,000 new cases of pancreatic cancer in the United States for 2021 with more than 47,000 deaths.